Of particular note, a pentylenetetrazol (PTZ)-induced epilepsy model demonstrated a significant antiepileptic effect, and its mechanism of action involves a targeted intervention in the AP-1/miR-155-5p/GLAST signaling cascade network: the compound reduces the downstream miR-155-5p expression level by inhibiting the AP-1 transcriptional activity, and at the same time reverses the miRNA inhibitory effect on the glutamate transporter GLAST in astrocytes. Here, SLC1A3 is linked to epilepsy.